Levetiracetam Pensa (Levetiracetam)

Levetiracetam is an antiepileptic drug used to control various seizure types across age groups.

• Partial seizures: reduces frequency and severity of focal seizures, improving daily functioning.
• Generalized tonic‑clonic seizures: helps achieve seizure freedom or significant reduction, supporting overall safety.
• Myoclonic seizures: decreases occurrence of rapid muscle jerks, aiding motor control.
• Adjunct therapy: may be combined with other antiepileptic agents to enhance overall seizure control.

• Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates calcium‑dependent exocytosis, stabilizing neuronal membranes and reducing hyper‑excitability. By decreasing the synchrony of neuronal firing, the drug lowers the likelihood of seizure initiation and propagation without directly affecting ion channels or G‑protein pathways. The precise downstream effects remain under investigation, but the overall result is a dampening of abnormal neuronal circuits implicated in epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness, often transient.
• Fatigue: feeling unusually tired or lacking energy during daily activities.
• Headache: mild to moderate cranial pain that may respond to analgesics.
• Irritability: mood changes or increased agitation, especially early in therapy.
• Nausea: mild stomach upset that usually resolves with continued use.
• Somnolence: increased sleepiness or drowsiness, particularly after dose escalation.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or breathing difficulty requiring immediate medical attention.
• Mood or behavior changes: depression, suicidal thoughts, aggression, or hostility that warrant prompt evaluation.
• Hematologic abnormalities: low blood cell counts or clotting issues, monitored through laboratory tests.
• Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement, a medical emergency.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: assess creatinine clearance and adjust dose in impaired patients.
• Psychiatric history: monitor for mood changes, depression, or suicidal ideation.
• Concomitant CNS depressants: use caution as combined effects may increase sedation.
• Pregnancy and lactation: evaluate risks versus benefits; limited data are available.
• Driving and operating machinery: advise patients about possible dizziness or drowsiness.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control.
• Phenobarbital: can lower levetiracetam concentrations, potentially compromising effectiveness.
• Phenytoin: may decrease levetiracetam exposure, requiring close monitoring.

Moderate Interactions (Monitor Closely)

• Alcohol: additive central nervous system depression may increase drowsiness.
• Opioids: combined use can enhance sedation and respiratory depression.
• Other antiepileptic drugs: dose adjustments may be needed to maintain therapeutic balance.